Subscribe to Newsletter
Inside the Lab Oncology, Precision medicine, Genetics and epigenetics, Biochemistry and molecular biology, Technology and innovation, Training and education

Oncomine Dx Target Test – an IVD NGS solution for every lab

With the ongoing development of precision oncology and more and more biomarkers entering routine clinical testing, a true end-to-end IVD solution, consolidating everything into one streamlined workflow, is needed in more pathology laboratories. The Oncomine Dx Target Test, based on next-generation sequencing (NGS), is now available in Europe and offers just that – 46 gene targets, including biomarkers associated with approved and investigative targeted therapies, all from one test, in one workflow, and in four days. Among the biomarkers tested are not only EGFR,ALK,ROS1 and BRAF but also cMET, NTRK1/2/3, RET, ERBB2, and others, currently in clinical trials.

Read the full article now

Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine